126 related articles for article (PubMed ID: 10447652)
21. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition.
Bank N; Coco M; Aynedjian HS
Am J Physiol; 1989 Jun; 256(6 Pt 2):F994-9. PubMed ID: 2500030
[TBL] [Abstract][Full Text] [Related]
22. Normalization of lens protein kinase Cgamma in galactosemic dogs by a novel aldose reductase inhibitor.
Takemoto DJ; Harris R; Brightman A; McGill J; Hua D; Davidson H; Fenwick B; Wagner LM
Vet Ophthalmol; 2004; 7(3):163-7. PubMed ID: 15091323
[TBL] [Abstract][Full Text] [Related]
23. The polyol pathway in retinal microangiopathy.
Robison WG; Kinoshita JH; Kador PF
Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
[TBL] [Abstract][Full Text] [Related]
24. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
[TBL] [Abstract][Full Text] [Related]
25. Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175.
Sato S; Mori K; Wyman M; Kador PF
Exp Eye Res; 1998 Feb; 66(2):217-22. PubMed ID: 9533847
[TBL] [Abstract][Full Text] [Related]
26. Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor.
Obrosova I; Faller A; Burgan J; Ostrow E; Williamson JR
Curr Eye Res; 1997 Jan; 16(1):34-43. PubMed ID: 9043821
[TBL] [Abstract][Full Text] [Related]
27. Effects of aldose reductase inhibitor, CT-112, on sugar alcohol accumulation in corneal epithelium of galactose-fed rats.
Awata T; Sogo S; Yamamoto Y
Jpn J Ophthalmol; 1986; 30(3):245-50. PubMed ID: 3097363
[TBL] [Abstract][Full Text] [Related]
28. Effect of aldose reductase inhibitors on lenticular dulcitol level in galactose fed rats.
Unakar NJ; Tsui JY; Johnson MJ
J Ocul Pharmacol; 1992; 8(3):199-212. PubMed ID: 1453083
[TBL] [Abstract][Full Text] [Related]
29. Aldose reductase inhibitor counteracts the enhanced expression of matrix metalloproteinase-10 and improves corneal wound healing in galactose-fed rats.
Takamura Y; Matsumoto T; Tomomatsu T; Matsumura T; Takihara Y; Inatani M
Mol Vis; 2013; 19():2477-86. PubMed ID: 24339723
[TBL] [Abstract][Full Text] [Related]
30. Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats.
Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Naruse K; Sasaki H; Mizuno K; Matsubara A; Kakuta H
Exp Physiol; 1995 Nov; 80(6):981-9. PubMed ID: 8962712
[TBL] [Abstract][Full Text] [Related]
31. Increased ocular blood flow and 125I-albumin permeation in galactose-fed rats: inhibition by sorbinil.
Tilton RG; Chang K; Weigel C; Eades D; Sherman WR; Kilo C; Williamson JR
Invest Ophthalmol Vis Sci; 1988 Jun; 29(6):861-8. PubMed ID: 3372163
[TBL] [Abstract][Full Text] [Related]
32. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
Vinores SA; Campochiaro PA
Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
[TBL] [Abstract][Full Text] [Related]
33. Inhibition in rat of development of in utero galactose-induced cataract by an aldose reductase inhibitor--a light microscopic study.
Teshima R; Taura T; Okamura R
Jpn J Ophthalmol; 1991; 35(3):317-24. PubMed ID: 1770672
[TBL] [Abstract][Full Text] [Related]
34. Aldose reductase activity and basement membrane thickening.
Frank RN
Metabolism; 1986 Apr; 35(4 Suppl 1):35-40. PubMed ID: 3083207
[TBL] [Abstract][Full Text] [Related]
35. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy.
Dagher Z; Park YS; Asnaghi V; Hoehn T; Gerhardinger C; Lorenzi M
Diabetes; 2004 Sep; 53(9):2404-11. PubMed ID: 15331552
[TBL] [Abstract][Full Text] [Related]
36. Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model.
Robison WG; Laver NM; Jacot JL; Glover JP
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2368-80. PubMed ID: 7591626
[TBL] [Abstract][Full Text] [Related]
37. Prefeeding of aldose reductase inhibitor and galactose cataractogenesis.
Unakar NJ; Tsui JY; Johnson MJ
Curr Eye Res; 1989 Oct; 8(10):997-1010. PubMed ID: 2558845
[TBL] [Abstract][Full Text] [Related]
38. Galactose-induced retinal microangiopathy in rats.
Kern TS; Engerman RL
Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):490-6. PubMed ID: 7843917
[TBL] [Abstract][Full Text] [Related]
39. Increased urinary prostaglandin excretion in galactose-fed rats.
Zager PG; Eaton RP; Frey HJ; Scavini M; Jackson JE
Metabolism; 1989 Jul; 38(7):603-5. PubMed ID: 2500576
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
Inaba M; Terada M; Nishizawa Y; Shioi A; Ishimura E; Otani S; Morii H
Metabolism; 1999 Jul; 48(7):904-9. PubMed ID: 10421234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
